Compare HCSG & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCSG | EYPT |
|---|---|---|
| Founded | 1976 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1994 | 2005 |
| Metric | HCSG | EYPT |
|---|---|---|
| Price | $24.87 | $13.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $22.67 | ★ $31.80 |
| AVG Volume (30 Days) | 729.3K | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.83 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $1,837,173,000.00 | $7,539,000.00 |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $5.22 | $3,115.57 |
| P/E Ratio | $67.97 | ★ N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $12.66 | $9.41 |
| 52 Week High | $25.55 | $19.11 |
| Indicator | HCSG | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 78.53 | 55.34 |
| Support Level | $18.36 | $12.01 |
| Resistance Level | N/A | $14.52 |
| Average True Range (ATR) | 0.71 | 1.05 |
| MACD | 0.27 | 0.08 |
| Stochastic Oscillator | 89.87 | 51.38 |
Healthcare Services Group Inc is a provider of housekeeping and facility management services to the healthcare industry. The company manages and evaluates its operations in two reportable segments: Environmental Services segment includes housekeeping, management of clients' housekeeping departments, cleaning, disinfecting and sanitizing, laundry, bed linen, and uniform services, linen and other services; and Dietary Segment includes dietary department services, food purchasing, meal preparation, and providing dietitian consulting services. Its clients are nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States of America. The Environmental Services segment derives maximum revenue.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.